PLoS ONE (Jan 2022)

The hypothalamic RFamide, QRFP, increases feeding and locomotor activity: The role of Gpr103 and orexin receptors.

  • Chris Cook,
  • Nicolas Nunn,
  • Amy A Worth,
  • David A Bechtold,
  • Todd Suter,
  • Susan Gackeheimer,
  • Lisa Foltz,
  • Paul J Emmerson,
  • Michael A Statnick,
  • Simon M Luckman

DOI
https://doi.org/10.1371/journal.pone.0275604
Journal volume & issue
Vol. 17, no. 10
p. e0275604

Abstract

Read online

Here we show that central administration of pyroglutamylated arginine-phenylamine-amide peptide (QRFP/26RFa) increases both food intake and locomotor activity, without any significant effect on energy expenditure, thermogenesis or reward. Germline knock out of either of the mouse QRFP receptor orthologs, Gpr103a and Gpr103b, did not produce a metabolic phenotype. However, both receptors are required for the effect of centrally administered QRFP to increase feeding and locomotor activity. As central injection of QRFP activated orexin/hypocretin neurons in the lateral hypothalamus, we compared the action of QRFP and orexin on behaviour. Both peptides increased arousal and locomotor activity. However, while orexin increased consummatory behaviour, QRFP also affected other appetitive behaviours. Furthermore, the feeding but not the locomotor response to QRFP, was blocked by co-administration of an orexin receptor 1 antagonist. These results suggest that QRFP agonism induces both appetitive and consummatory behaviour, but only the latter is dependent on orexin/hypocretin receptor signalling.